AltMountain

Seven Fleet Capital Management LP

Location not listed · CRD 335203
Hedge fund manager

Seven Fleet Capital Management LP is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $434.6 million in regulatory assets under management. Its private funds, of all types, hold $434.6 million in gross assets. Over a longer period they returned an estimated +32.6% from Q1 2026 to Q1 2026, compared with -4.6% for the S&P 500, based on 13F filings.

Regulatory assets under management
$434.6 millionForm ADV Item 5.F
Gross assets of private funds
$434.6 millionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
4Form ADV Item 5.A
Registration
SEC-registered adviserCRD 335203
Latest Form ADV
07/06/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 1 quarters+32.6%Q1 2026 – Q1 2026
S&P 500-4.6%Same quarters, price only
13F holdings$605.9 million96 positions, 2026-06-30
$95$114$133Q1 202613F est. $133S&P 500 $95
QuarterEst. 13F returnS&P 500
Q1 2026+32.6%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 85 share positions ($511,733,165) reported by Seven Fleet Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • CG Oncology Inc26.13%
  • Tango Therapeutics Inc10.89%
  • Revolution Medicines Inc10.61%
  • Pharvaris N V4.34%
  • Entera Bio LTD3.90%
  • Liquidia Corporation3.53%
  • Arrivent Biopharma Inc2.67%
  • Enliven Therapeutics Inc2.35%
  • Avalo Therapeutics Inc2.31%
  • Xencor Inc2.17%
StockValue% of 13F portfolioSharesShares vs prior quarter
CG Oncology Inc$133,715,27026.13%1,886,236Unchanged
Tango Therapeutics Inc$55,709,95710.89%2,232,864-30.83%
Revolution Medicines Inc$54,309,33310.61%264,588+9.32%
Pharvaris N V$22,206,6644.34%700,084-9.61%
Entera Bio LTD$19,970,5853.90%6,862,744+3,486.41%
Liquidia Corporation$18,043,2823.53%596,275+16.19%
Arrivent Biopharma Inc$13,661,5182.67%451,173+82.95%
Enliven Therapeutics Inc$12,008,1092.35%261,957-28.31%
Avalo Therapeutics Inc$11,844,8782.31%772,660+0.25%
Xencor Inc$11,101,1782.17%444,937+20.81%
Roivant Sciences LTD$10,615,5402.07%290,280+31.87%
Abivax SA$9,830,1111.92%99,274-10.83%
Assembly Biosciences Inc$9,805,6891.92%417,441-3.63%
Veradermics Inc$9,698,4001.90%80,000Unchanged
Protagonist Therapeutics Inc$6,432,8971.26%45,659+0.57%
Damora Therapeutics Inc Com SHS$6,137,9821.20%288,439New
Century Therapeutics Inc$6,083,1331.19%4,421,739+1.70%
Eupraxia Pharmaceuticals Inc$5,207,6301.02%572,267-6.31%
Axsome Therapeutics Inc.$4,437,5300.87%24,066-16.51%
Sagimet Biosciences Inc$4,239,6360.83%429,113+6.34%
Zentalis Pharmaceuticals Inc$4,166,7200.81%1,504,231+373.62%
Definium Therapeutics Inc$4,135,1050.81%108,647-26.91%
Dianthus Therapeutics Inc$4,088,3380.80%46,432-28.26%
Silence Therapeutics PLC$3,825,5000.75%350,000+482.29%
Tarsus Pharmaceuticals Inc$3,814,9430.75%48,530-58.55%
Immunic Inc$3,660,9270.72%687,240New
Taysha Gene Therapies Inc$3,652,5000.71%750,000-50.15%
Cytokinetics Inc$3,542,5310.69%53,748-54.54%
Minerva Neurosciences Inc$3,354,6000.66%1,001,373Unchanged
Relay Therapeutics Inc$3,352,4810.66%185,733+4.21%
Zai Lab LTD$3,118,5240.61%118,395-12.96%
Praxis Precision Medicines I$3,054,7110.60%10,489+39.11%
Cytomx Therapeutics Inc.$2,952,2830.58%1,085,398Unchanged
Editas Medicine Inc$2,944,8020.58%1,915,871-4.00%
Sab Biotherapeutics Inc$2,386,2870.47%752,772+2.27%
Ascendis Pharma A/s$2,150,7150.42%9,440-20.47%
Adlai Nortye LTD$1,858,9600.36%116,185+2.63%
Sutro Biopharma Inc$1,609,2920.31%99,894-37.22%
United Therapeutics Corp Del$1,593,1570.31%2,940New
Inventiva SA$1,528,9180.30%414,341+107.02%
Harmony Biosciences Hldgs In$1,487,9540.29%37,900New
An2 Therapeutics Inc$1,352,9240.26%254,309+21.71%
Celldex Therapeutics Inc New$1,324,5320.26%40,868-52.84%
Summit Therapeutics Inc$1,296,1180.25%76,648+4.57%
Vaxcyte Inc$1,255,5550.25%22,066-25.95%
Tcgx Acquisition Corp$1,251,0000.24%100,000New
Contineum Therapeutics Inc$1,162,8970.23%86,654+43.13%
Biohaven LTD$1,084,3000.21%81,221New
Spyre Therapeutics Inc$1,033,7270.20%11,611-12.70%
Inmed Pharmaceuticals Inc$1,000,0000.20%1,069,519New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 20 new positions, 31 sold out, 26 increased, 31 reduced and 8 unchanged.

Number of positions (a count, not dollars)

  • New positions20
  • Increased26
  • Unchanged8
  • Reduced31
  • Sold out31

New positions

StockValueShares
Damora Therapeutics Inc Com SHS$6,137,982288,439
Immunic Inc$3,660,927687,240
United Therapeutics Corp Del$1,593,1572,940
Harmony Biosciences Hldgs In$1,487,95437,900
Tcgx Acquisition Corp$1,251,000100,000
Biohaven LTD$1,084,30081,221
Inmed Pharmaceuticals Inc$1,000,0001,069,519
Yarrow Bioscience Inc$900,80040,000
Lisata Therapeutics Inc$534,832371,411
Avalyn Pharmaceuticals Inc$419,08814,710
Quince Therapeutics Inc$371,77911,989
Immatics N.V$346,81039,500
Obsidian Therapeutics Inc$316,84723,077
Faeth Therapeutics Inc$303,46710,204
Tectonic Therapeutic Inc$279,48012,000
Disc Medicine Inc$268,3864,100
Abeona Therapeutics Inc$255,91148,745
Aclaris Therapeutics Inc$232,49244,200
Inovio Pharmaceuticals Inc$167,262137,100
Processa Pharmaceuticals Inc$30,01218,300

Sold out

StockValue at Jun 30, 2026Shares held then
Mirum Pharmaceuticals Inc$12,923,709110,393
Damora Therapeutics Inc$7,398,024284,430
Madrigal Pharmaceuticals Inc$2,670,2524,973
Relmada Therapeutics Inc$2,409,994348,265
Agios Pharmaceuticals Inc$2,111,55956,900
Xenon Pharmaceuticals Inc$2,084,46833,300
Savara Inc$1,904,074309,103
Celcuity Inc$1,700,28416,252
Syndax Pharmaceuticals Inc$1,645,04677,930
Structure Therapeutics Inc$1,441,57226,800
Alkermes PLC$1,220,01823,285
Trevi Therapeutics Inc$833,43045,598
Voyager Therapeutics Inc$771,860230,406
Engene Therapeutics Inc$711,142411,065
Larimar Therapeutics Inc$704,309230,921
Ishares TR$681,85813,800
Krystal Biotech Inc$659,3431,774
Evolus Inc$541,71678,057
Biocryst Pharmaceuticals Inc$510,24051,024
Monte Rosa Therapeutics Inc$406,56016,800

Largest increases

StockChange in sharesChangeValue nowShares now
Entera Bio LTD+6,671,390+3,486.41%$19,970,5856,862,744
Arrivent Biopharma Inc+204,567+82.95%$13,661,518451,173
Revolution Medicines Inc+22,559+9.32%$54,309,333264,588
Zentalis Pharmaceuticals Inc+1,186,631+373.62%$4,166,7201,504,231
Silence Therapeutics PLC+289,893+482.29%$3,825,500350,000
Roivant Sciences LTD+70,154+31.87%$10,615,540290,280
Liquidia Corporation+83,069+16.19%$18,043,282596,275
Xencor Inc+76,632+20.81%$11,101,178444,937
Praxis Precision Medicines I+2,949+39.11%$3,054,71110,489
Inventiva SA+214,200+107.02%$1,528,918414,341
Contineum Therapeutics Inc+26,113+43.13%$1,162,89786,654
Sagimet Biosciences Inc+25,568+6.34%$4,239,636429,113
An2 Therapeutics Inc+45,363+21.71%$1,352,924254,309
Beam Therapeutics Inc+7,040+79.96%$387,38615,844
Relay Therapeutics Inc+7,511+4.21%$3,352,481185,733
Amylyx Pharmaceuticals Inc+4,018+27.63%$540,03818,558
Century Therapeutics Inc+73,913+1.70%$6,083,1334,421,739
Summit Therapeutics Inc+3,348+4.57%$1,296,11876,648
Sab Biotherapeutics Inc+16,695+2.27%$2,386,287752,772
Adlai Nortye LTD+2,978+2.63%$1,858,960116,185

Largest reductions

StockChange in sharesChangeValue nowShares now
Tango Therapeutics Inc-995,280-30.83%$55,709,9572,232,864
Tarsus Pharmaceuticals Inc-68,537-58.55%$3,814,94348,530
Enliven Therapeutics Inc-103,429-28.31%$12,008,109261,957
Cytokinetics Inc-64,492-54.54%$3,542,53153,748
Cogent Biosciences Inc-128,184-86.90%$618,81919,326
Erasca Inc-273,031-88.64%$512,74834,976
Taysha Gene Therapies Inc-754,400-50.15%$3,652,500750,000
Pharvaris N V-74,417-9.61%$22,206,664700,084
Dianthus Therapeutics Inc-18,291-28.26%$4,088,33846,432
Definium Therapeutics Inc-40,000-26.91%$4,135,105108,647
Celldex Therapeutics Inc New-45,796-52.84%$1,324,53240,868
Abivax SA-12,060-10.83%$9,830,11199,274
Ideaya Biosciences Inc-29,915-79.00%$305,4397,950
Geron Corp-798,328-75.51%$318,447258,900
Sutro Biopharma Inc-59,224-37.22%$1,609,29299,894
Axsome Therapeutics Inc.-4,760-16.51%$4,437,53024,066
C4 Therapeutics Inc-241,169-63.27%$466,200140,000
Opus Genetics Inc-133,137-93.01%$48,40010,000
Ascendis Pharma A/s-2,429-20.47%$2,150,7159,440
Zai Lab LTD-17,621-12.96%$3,118,524118,395

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Entera Bio, Ltd. (the "Issuer")13G4.1%7,053,898Aug 4, 2026SEC.gov ↗
CytomX Therapeutics, Inc.13G amendment0.5%1,085,398May 15, 2026SEC.gov ↗
Veradermics, Inc13D0.2%80,000May 5, 2026SEC.gov ↗
CG Oncology, Inc.13D amendment1.9%1,515,151Oct 28, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 28, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (4)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠